GeneDx (NASDAQ:WGS) CFO Sells $554,618.85 in Stock

GeneDx Holdings Corp. (NASDAQ:WGS) CFO Kevin Feeley sold 3,855 shares of the stock in a transaction dated Tuesday, December 16th. The shares were sold at an average price of $143.87, for a total transaction of $554,618.85. Following the completion of the sale, the chief financial officer directly owned 8,731 shares in the company, valued at approximately $1,256,128.97. The trade was a 30.63% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Kevin Feeley also recently made the following trade(s):

• On Tuesday, December 9th, Kevin Feeley sold 1,266 shares of GeneDx stock. The stock was sold at an average price of $159.28, for a total transaction of $201,648.48.
• On Wednesday, October 29th, Kevin Feeley sold 388 shares of GeneDx stock. The shares were sold at an average price of $136.54, for a total transaction of $52,977.52.

GeneDx Trading Up 3.0%

Shares of WGS opened at $140.44 on Friday. The company has a debt-to-equity ratio of 0.18, a current ratio of 2.71 and a quick ratio of 2.59. GeneDx Holdings Corp. has a 1-year low of $55.17 and a 1-year high of $170.87. The stock has a market cap of $4.06 billion, a price-to-earnings ratio of 1,560.44 and a beta of 1.99. The firm has a 50 day simple moving average of $141.11 and a 200-day simple moving average of $116.27.

GeneDx (NASDAQ:WGS) last announced its earnings results on Tuesday, October 28th. The company reported $0.49 EPS for the quarter, beating analysts’ consensus estimates of $0.28 by $0.21. The firm had revenue of $116.74 million for the quarter, compared to analysts’ expectations of $104.33 million. GeneDx had a return on equity of 20.22% and a net margin of 0.52%. Equities analysts forecast that GeneDx Holdings Corp. will post 0.97 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on WGS. Canaccord Genuity Group set a $160.00 target price on shares of GeneDx and gave the company a “buy” rating in a report on Wednesday, October 29th. Piper Sandler upped their price objective on shares of GeneDx from $120.00 to $140.00 and gave the company an “overweight” rating in a research note on Thursday, September 11th. Guggenheim restated a “buy” rating and set a $170.00 target price (up previously from $115.00) on shares of GeneDx in a research report on Wednesday, October 29th. Wells Fargo & Company set a $155.00 price target on GeneDx and gave the company an “equal weight” rating in a report on Monday, December 15th. Finally, Weiss Ratings reissued a “sell (d)” rating on shares of GeneDx in a research note on Wednesday, October 8th. Seven research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $134.78.

Hedge Funds Weigh In On GeneDx

Several institutional investors and hedge funds have recently bought and sold shares of WGS. Jones Financial Companies Lllp boosted its holdings in shares of GeneDx by 664.3% in the 3rd quarter. Jones Financial Companies Lllp now owns 214 shares of the company’s stock valued at $25,000 after purchasing an additional 186 shares during the last quarter. Quarry LP raised its position in shares of GeneDx by 248.8% in the 3rd quarter. Quarry LP now owns 293 shares of the company’s stock worth $32,000 after buying an additional 209 shares during the period. US Bancorp DE boosted its holdings in GeneDx by 3,223.5% in the first quarter. US Bancorp DE now owns 565 shares of the company’s stock valued at $50,000 after acquiring an additional 548 shares during the last quarter. Gordian Capital Singapore Pte Ltd purchased a new stake in GeneDx during the third quarter valued at about $65,000. Finally, AlphaQuest LLC grew its position in GeneDx by 351.5% during the second quarter. AlphaQuest LLC now owns 763 shares of the company’s stock valued at $70,000 after acquiring an additional 594 shares during the period. Institutional investors and hedge funds own 61.72% of the company’s stock.

About GeneDx

GeneDx is a clinical diagnostics company specializing in comprehensive genetic and genomic testing for rare and inherited disorders. The company offers a broad portfolio of assays, including targeted gene panels, whole exome sequencing, whole genome sequencing and chromosomal microarray analysis. GeneDx’s laboratory services support the diagnosis of a wide range of conditions—from rare pediatric diseases and hereditary cancer syndromes to neuromuscular and metabolic disorders—by providing clinicians with detailed variant interpretation and reporting.

Founded in 2000 and based in Gaithersburg, Maryland, GeneDx was established with the aim of accelerating the translation of genomic discoveries into clinical care.